Tanja[a]
SOURCE: Celgene Corporation
THALOMID(R) Clinical Trials To Be Discussed At Chemotherapy Foundation Symposium
Data on THALOMID in Hematological and Solid Tumor Cancers to be Reported
WARREN, N.J.,
Celgene Corporation announced today that investigators from leading cancer research centers will present clinical data on THALOMID® (thalidomide) in a variety of hematological and solid tumor cancers at the Chemotherapy Foundation Symposium XIX sponsored by Mount Sinai School of Medicine. The conference, held in New York City from November 7 through November 10, will highlight innovative cancer therapies.
Investigators will discuss data from THALOMID clinical trials in the following sessions:
* Wednesday, November 7 BLT-D (Biaxin, Thalidomide and
Dexamethasone): Non-myelosuppressive in
Myeloma and Waldenstrom´s Macroglobulinemia
Morton Coleman, M.D., Director, Center for
Lymphoma and Myeloma, Weill Medical College
of Cornell University
* Thursday, November 8 Developmental Therapeutics for Multiple
Myeloma: A Road Map for the Future
Bart Barlogie, M.D., Ph.D., Director,
Arkansas Cancer Research Center
* Thursday, November 8 Thalidomide Therapy in Advanced Renal Cell
Cancer Robert Amato, M.D., Associate
Professor, Baylor College of Medicine
* Friday, November 9 Metastatic Melanoma in the Brain: New Approaches
Wen-Jen Hwu, M.D., Associate Attending
Physician, Memorial Sloan-Kettering Cancer
Center
* Saturday, November 10 Therapeutic Advances in the Management of
Multiple Myeloma
Mohamad A. Hussein, M.D, Director, Multiple
Myeloma Program, Cleveland Clinic Taussig
Cancer Center
Celgene Corporation, located in Warren, New Jersey, is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and inflammatory diseases through gene regulation.
Safety Notice
Thalidomide is contraindicated in pregnant women and women capable of becoming pregnant. Even a single capsule taken by a pregnant woman can cause severe birth defects or death to an unborn baby. To minimize this risk, only prescribers and pharmacies registered with the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.®) distribution program may prescribe or dispense THALOMID® (thalidomide). Other adverse drug reactions known to be associated with thalidomide therapy include: peripheral neuropathy, a common, potentially severe side effect that may be irreversible; drowsiness/somnolence; dizziness/orthostatic hypotension; neutropenia; hypersensitivity reactions; and increased HIV-viral load. Physicians should consult full prescribing information about these and other adverse reactions prior to initiating treatment with THALOMID®.
THALOMID® (thalidomide), manufactured by Celgene Corporation, received U.S. Food and Drug Administration (FDA) clearance on July 16, 1998 for the acute treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of cutaneous manifestation recurrences. THALOMID® is not indicated as monotherapy for ENL treatment in the presence of moderate to severe neuritis.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company´s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company´s filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.